Group 1 - Huafeng Co., Ltd. announced a stock suspension due to a potential change in control after signing a share transfer intention agreement [1] - Keshida plans to reduce its shareholding by up to 424,000 shares, representing 0.07% of its total share capital [1] - Jinqilin intends to distribute a cash dividend of 0.10 yuan per share, totaling 19.61 million yuan [1] Group 2 - Rejingshi Biotech has repurchased 904,100 shares, accounting for 0.98% of its total share capital, with a total expenditure of 150 million yuan [2] - Yishitong has repurchased 1,236,500 shares, representing 0.619% of its total share capital, with a total expenditure of approximately 33.49 million yuan [2] Group 3 - Hanjia Design announced the release of a detention on its subsidiary's chairman, allowing him to resume duties [4] - Qingmu Technology plans to acquire 65.83% of Vitalis Pharma AS for 300 million Norwegian Krone (approximately 212 million yuan) [4] - Anda Intelligent's shareholder plans to reduce its stake by up to 2.74% [4] Group 4 - Wansheng Intelligent is a candidate for a project with a pre-bid amount of approximately 42.99 million yuan, representing 4.56% of its audited revenue for 2024 [4] - Yipin Hong received a drug registration certificate for a medication used to treat Alzheimer's symptoms [4] Group 5 - *ST Sansheng received a total of 254 million yuan from restructuring investors [4] - Haichuang Pharmaceutical received approval for clinical trials of HP518 tablets for advanced prostate cancer treatment [4] Group 6 - Ningbo Huaxiang's subsidiary plans to invest 5 million yuan in a venture capital fund focusing on intelligent industries [4] - Petty Co. plans to repurchase shares worth 50 to 70 million yuan [4] Group 7 - Tongji Technology's subsidiary won a construction project with a bid price of 866 million yuan [4] - Prolo Pharmaceutical received a drug registration certificate for a generic drug [4] Group 8 - Jingyan Technology plans to use up to 1.6 billion yuan of idle funds for financial management [4] - Furan De received government subsidies totaling 34.65 million yuan [4] Group 9 - David Medical's subsidiary's medical device registration has been accepted [4] - Jusaylong plans to increase its subsidiary's capital by 170 million yuan through debt-to-equity conversion [4] Group 10 - Heng Rui Pharmaceutical's application for a drug license has been accepted by the National Medical Products Administration [4] - Lege Co. plans to increase its stake in the company by 40 to 80 million yuan [4] Group 11 - New Beiyang's subsidiary won a project with the Bank of Communications [4] - Jiangxi Changyun plans to publicly transfer land use rights and buildings with a starting price of 7.79 million yuan [4] Group 12 - Shenqi Pharmaceutical's subsidiary has paid approximately 16.67 million yuan in tax and penalties [4] - Panjiang Co. plans to invest 1.334 billion yuan in a power plant project [4] Group 13 - Fashilong's vice president resigned for personal reasons [4] - Chunxue Food received government subsidies of 3.79 million yuan [4] Group 14 - China Galaxy completed the repayment of a short-term financing bond totaling 3.025 billion yuan [4] - Jiuzhou Pharmaceutical received approval for a chemical raw material drug [4] Group 15 - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund [4]

Core Viewpoint - Jiuzhou Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Tofisopam Tosylate, an oral anticoagulant drug aimed at preventing strokes and systemic embolism in patients with non-valvular atrial fibrillation, as well as treating or preventing deep vein thrombosis and pulmonary embolism [1] Company Summary - The company submitted the marketing application for Tofisopam Tosylate to the National Medical Products Administration in July 2024 and has recently obtained the approval notification [1] - Cumulative research and development investment in Tofisopam Tosylate has reached approximately RMB 6.69 million [1] Industry Summary - The main manufacturers of Tofisopam Tosylate in China include Xiansheng Pharmaceutical Co., Ltd. and Shandong New Era Pharmaceutical Co., Ltd. [1] - Sales of Tofisopam Tosylate tablets in domestic sample hospitals and urban pharmacies amounted to approximately RMB 361 million in 2023 [1]

Core Viewpoint - The approval of tolvaptan sulfate by the National Medical Products Administration enhances the company's product portfolio and competitiveness, although it is expected to have no significant short-term impact on performance due to uncertainties in drug production and sales [1] Summary by Categories Regulatory Approval - The company has received the approval notice for the listing application of tolvaptan sulfate from the National Medical Products Administration [1] - The drug is an oral anticoagulant, with the listing application submitted in July 2024 [1] Research and Development Investment - The company has invested approximately 6.69 million yuan in the research and development of this active pharmaceutical ingredient [1] Market Performance - In 2023, the sales revenue of tolvaptan sulfate tablets in domestic sample hospitals and urban pharmacies was approximately 361 million yuan [1] - The approval is expected to enrich the company's product structure and enhance competitiveness [1]

证券代码：603456 证券简称：九洲药业 公告编号：2025-068 浙江九洲药业股份有限公司 关于公司收到化学原料药上市申请批准通知书 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江九洲药业股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）颁发的关于甲苯磺酸艾多沙班的《化学原料 药上市申请批准通知书》（通知书编号：2025YS01026），具体情况如下： 一、药品的基本情况 药品名称：甲苯磺酸艾多沙班 注册标准编号：YBY71722025 包装规格：1kg/桶，2kg/桶，5kg/桶，10kg/桶，15kg/桶，20kg/桶，25kg/桶 申请事项：境内生产化学原料药上市申请 生产企业：浙江九洲药业股份有限公司，浙江省台州市椒江区外沙路工业区 （外沙路 99 号） 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 二、药品其他相关情况 甲苯磺酸艾多沙班是一种口服抗凝药物，主要用于预防 ...

Core Viewpoint - Jiuzhou Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of tolvaptan sulfate, an oral anticoagulant drug [1] Group 1: Company Information - Jiuzhou Pharmaceutical (603456) announced the receipt of a marketing approval notification for tolvaptan sulfate on November 24 [1] - Tolvaptan sulfate is primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1]

Core Viewpoint - The company, Jiuzhou Pharmaceutical, has received approval from the National Medical Products Administration for the marketing application of Tofisopam Tosylate, an oral anticoagulant drug [1] Group 1: Company Information - Jiuzhou Pharmaceutical (603456.SH) announced the receipt of the marketing approval notification for Tofisopam Tosylate [1] - Tofisopam Tosylate is primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1]

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) has received the approval notice for the marketing application of Tofisopam Tosylate from the National Medical Products Administration, marking a significant milestone for the company in the oral anticoagulant market [1] Group 1 - The approved drug, Tofisopam Tosylate, is an oral anticoagulant primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1] - The drug is also indicated for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1]

（文章来源：证券日报） 证券日报网讯九洲药业11月21日在互动平台回答投资者提问时表示，股价表现受宏观环境、行业政策、 市场行情及板块轮动等多重因素综合影响，为稳定市场预期、传递长期发展信心，公司已扎实推进系列 市值管理举措：2025年股份回购计划实施完毕，2024年回购库存股完成注销，同时顺利实施2025年半年 度分红方案。未来公司将以稳健经营为基础，积极向资本市场传递核心价值，切实为创造长期、稳定的 投资回报。 ...

Market Overview - The medical services sector experienced a decline of 2.71% on November 21, with Baihua Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Notable gainers included Yangguang Nuohua, which rose by 4.47% to a closing price of 61.21, with a trading volume of 86,300 shares and a transaction value of 530 million [1] - Baihua Pharmaceutical saw a significant decline of 9.67%, closing at 9.06, with a trading volume of 292,400 shares and a transaction value of 275 million [2] - Other notable decliners included Chengda Pharmaceutical (-9.58%), Berry Genomics (-8.67%), and Guangzheng Eye Hospital (-7.26%) [2] Capital Flow - The medical services sector experienced a net outflow of 1.325 billion in institutional funds, while retail investors saw a net inflow of 1.332 billion [2] - The table of capital flow indicates that major stocks like Yangguang Nuohua had a net inflow of 10.986 million from institutional investors, while retail investors had a net inflow of 1.374 million [3]

Core Insights - On November 20, Jiuzhou Pharmaceutical experienced a decline of 2.09% with a trading volume of 487 million yuan, indicating market volatility [1] - The company reported a financing buy-in of 65.75 million yuan and a net financing buy of 6.15 million yuan on the same day, reflecting investor interest despite the stock price drop [1] - As of September 30, Jiuzhou Pharmaceutical achieved a revenue of 4.16 billion yuan, marking a year-on-year growth of 4.92%, and a net profit of 748 million yuan, which is an 18.51% increase compared to the previous year [2] Financing and Trading Activity - Jiuzhou Pharmaceutical's financing balance reached 620 million yuan, accounting for 3.52% of its market capitalization, indicating a high level of leverage [1] - The company’s margin trading showed a low short-selling balance of 2.68 million yuan, suggesting limited bearish sentiment among investors [1] - The stock's financing balance is above the 90th percentile of the past year, indicating a high level of investor engagement [1] Shareholder and Dividend Information - As of September 30, the number of Jiuzhou Pharmaceutical shareholders increased by 10.22% to 59,200, while the average number of circulating shares per shareholder decreased by 9.27% [2] - The company has distributed a total of 2.183 billion yuan in dividends since its A-share listing, with 1.245 billion yuan distributed over the last three years [3] - Major institutional shareholders include Hong Kong Central Clearing Limited and China Europe Medical Health Mixed A, with both increasing their holdings [3]